

# Remdesivir – COVID-19 – India (Repurposing Scan)

Report ID: REP-20251217-7d2fdd

Generated At: 2025-12-17T11:11:01.562514

Format: pdf

## Executive Summary

- Remdesivir, also known by its synonyms GS-5734 and Veklury, is recommended by authoritative guidelines such as WHO and NICE for treatment of hospitalized COVID-19 patients under specific conditions. Recent publications between 2019 and 2024 indicate clinical and case report studies on remdesivir use, including safety and treatment outcomes, particularly in special populations like patients with severe chronic kidney disease. Indian news sources report on regulatory approvals, local guideline issuance, supply challenges, and legal actions related to remdesivir use in COVID-19 management within India. This reflects ongoing monitoring and management of remdesivir use in the region in the COVID-19 pandemic context.

## Clinical Trials

### Summary

- Active trials: 3
- Completed trials: 2

### Phase distribution

- Observational: 1
- Phase 1: 0
- Phase 2: 2
- Phase 3: 1
- Phase 4: 0

### Highlights

- No Phase III trials identified in India

## Top Trials

Trial ID	Title	Phase	Status	Start Date
NCT04610541	Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients	Phase 3	Active	2020-10-12
NCT04647695	An Open-label Randomized Controlled Trial on Interferon 2-β and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection	Phase 2	Active	2020-11-20
NCT04345419	Remdesivir in COVID-19 Treatment: A Randomised Trial	Phase 2	Completed	2020-06-16
NCT04582266	Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States	Observational	Completed	2021-03-31
NCT04560231	Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study	EAR-LY_Phase 1	Active	2020-06-01

## Guidelines and Literature

### Guidelines

- WHO Guidelines: Remdesivir is recommended for treatment of COVID-19 in hospitalized patients under specific conditions as per WHO guidance.  
 Publisher: World Health Organization | Date: 2020-03-27  
<https://www.who.int/publications/guidelines>
- NICE Guidelines: NICE recommends remdesivir as an antiviral treatment option for hospitalized COVID-19 patients requiring oxygen.  
 Publisher: National Institute for Health and Care Excellence (NICE) | Date: 2020-12-01  
<https://www.nice.org.uk/guidance>

### Publications

- PMID 39816292 (2024): Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.  
 Journal: Cureus  
 Finding: Title suggests a case report on sequential treatment with remdesivir and molnupiravir for prolonged COVID-19.
- PMID 39811032 (2024): Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.  
 Journal: International journal of critical illness and injury science  
 Finding: Title suggests analysis of bradycardia incidence associated with remdesivir use in COVID-19.

- PMID 39739156 (2025): Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan.  
 Journal: Clinical and experimental nephrology  
 Finding: Title suggests research on treatment patterns and outcomes of remdesivir in COVID-19 patients with severe CKD.

- PMID 39743047 (2025): Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deaza-purine nucleoside analogs as anti-SARS-CoV-2 agents.

Journal: Antiviral research

Finding: Title suggests development and evaluation of novel nucleoside analogs as anti-SARS-CoV-2 agents.

## News Signals

- Black marketing Remdesivir in Covid: Two get two years in jail - Times of India

Times of India | 2025-05-28

Report on legal actions against black marketing of Remdesivir during COVID-19 in India.

<https://news.google.com/rss/articles/CBMi0AFBV95cUxOaUNITURESII0alNHb0lUOXg2ay1pMWgwN2pEcU5vMm1HRU90Tw00Nm-tiMz6NEUxQ0hKX2E2MGhNeWNIQWg2NjA3ZGRVakNfWTIDMIBiSkN6QIdIclZXMMlVZjluMIV5N05ZYWt-SZ2JiRXNlcVNDYVZ6MTc5M3U1YzFQYjVzd3pTTHkzdlk1bHM1ZXhDTGdFWUpvRnFUEUtSHdKZnoxRXdyOEJ0bTd4NndKV-GRFYXI2WDZYV3BaTHRveHFYTDIZVmprod3lZMnh00gHWAUFVX3lxTE9SVEZkVThmR3duZGxlejFIWGROQ2tibTh4UIFZFhiNWfSkNidkZDaWhUU0FpaElxdC1fVhgweWZLaDV4SmrFRVcyQWhqMUMyaFpz25fQ09sLWRnWXlvRmxzc0h0QVkbWJYSzR-felFXYIYzMFV0MXRmTmhiMvvQVFNEV29udlJwbFBlaC1VcnEtboJwUC1LUmUzdWQ4NWVseWx4VXRuUmVVdEJNcj-ZLVHR1ZIB6M1k4cEVzZldsU1Z6N01XV0VsY2JiLXNMenRPRDJuNXc?oc=5>

- Coronavirus: Pune Municipal Corporation Issues Guidelines for Use of Remdesivir in COVID-19 Patients - The Bridge Chronicle

The Bridge Chronicle | 2025-05-29

Local Indian guidelines issued for the use of Remdesivir in COVID-19 patients by Pune Municipal Corporation.

<https://news.google.com/rss/articles/CBMiogFBVV95cUxORKzIRTJWZXN1RElqS25TSkRid29pb3M4dIRGdU1Lbd5TU51QUQwVGhU-UlZQMkhQMDdma3Jxa2FxRW9mcWJPVmtkVXIDRWg5RmR6S3VfY01TSzhqaUJLcdXbdzndlX0g4SmNxQVBOZGIySFdu-aTJQLU9UMIR0QnBveHppUUZPR01xcVZ0a0RzclJpTWhrUGV0Nzl0NFhFYIHSAA8BQVVeXFMTUlXyNQ5XzhoRkV5Q0QwcUN-hUzRhSDRpOVNzb050UnRYaE9fWFVjalFraEhXSVZNaVJDeT14RVdUYmk3X1h6UmU5MzJ5LVdWVFPWkFLTFh1RnVucUtMSHBsM-mdCTVRvcUJVUjxdVQ4R0hHU1k0bVVA01pbkpxRkxCdXJXX1EwbkktWEtTLXpaSEZNY0czRkloNFBsbmFPNFF6RThYb3Zu-UzhoWUJ4TQ?oc=5>

- What does the widespread use of Remdesivir in COVID-19 management in India and short supply of it teach us? - orfonline.org

orfonline.org | 2021-05-06

Analysis of remdesivir supply challenges and usage during COVID-19 in India.

<https://news.google.com/rss/articles/CBMimAFBV95cUxQT0x1WU9UOFFhMkhmN3NsS3ZzeHpTR3FGVmVNa2E3RnBGTjh-HcG5Dc3hITFNKYU5CQVVnbTFJNld4SWlzTkVKYU1TEFjaFZ5Q0pscnyFMURBSENUQ19QLWhhdkluRn-NoMGwtX1Jad3BaOVJzcXZuRk15QWh0R0QxMm1hSmZhR1dtVUR0U1FnVFn6MDRxTzVQVg?oc=5>

- COVID digest: India bans export of remdesivir treatment drug - DW

DW | 2021-04-11

India banned export of Remdesivir drug amid COVID-19 crisis to ensure local availability.

<https://news.google.com/rss/articles/CBMiqwFBVV95cUxNeUc5MXhhUXh4OXhQbE5Ob1ROWEtscTdxU0xyYksxZml3c1hudWNwR-mdieFVOU3oybnN5LWpiUUVpR05ad3QxNI9ua3JmdW5SOUN0Qkp6LTNrMkRKdFA0M1JTRVBQd0c5cGdNSktxX0Vybna-MWVFQkJiNG5Cb0dDQXFETDVGMFdMEpQS0Y1cFctWWNXNUk5anR6bFvkMII3UjVZOOGxZaFd4dFXSAasBQVvfeXFMTIR-ZOUFsTWdyNVlueEdTdTzrc21KMENtBGNpQIBMZEgxc1Bydy15SnBUNldQVmxUZGFOaGVSQ-jo1VENOX2QwekVWeXNNskoc3BZSWpsM0ZTeE9uSG1Zb1A2UHJITEowSHNIQ0xIVDVSbXg1ZU1MSjhFvzZwRzE0VHI5SjN-fWUU2YWUzejTZVhIz1raDNBTUNGdFdxX2hVVUdqdzVQME5MdDZj?oc=5>

- India approves remdesivir for restricted emergency use in COVID-19 patients - European Pharmaceutical Review

European Pharmaceutical Review | 2020-07-07

India approved remdesivir for restricted emergency use in COVID-19 patients.

<https://news.google.com/rss/articles/CBMizgFBVV95cUxNVzk1UW5tNIRhb3FhNkUxZU41bEFxeWVidUlyVUNmUjBpV3hhYUliSERXS0VDTTU2cmZGNEhsVndkejZ4Q3F3ZjFSN2dmLU95TGxJWXhITkRmelBmNTRBWEZ2aEIEcEdzRGpf25lbEpIZGxtZ2NPVjf-SOXFUMkJIN2oydm9nMTIYUIJQb2xsaXVaS0t4YzRoRjBKbHJQclVEMko4dk1pNFLwRnNleHpvMnhTWFhubE9zV1Y0TDFWeGlrUWpoTEIzeER4SWFQdw?oc=5>

## Repurposing Options

- Targeted subgroup usage

Rationale: Remdesivir, also known by its synonyms GS-5734 and Veklury, is recommended by authoritative guidelines such as WHO and NICE for treatment of hospitalized COVID-19 patients under specific conditions. Recent publications between 2019 and 2024 indicate clinical and case report studies on remdesivir use, including safety and treatment outcomes, particularly in special populations like patients with severe chronic kidney disease. Indian news sources report on regulatory approvals, local guideline issuance, supply challenges, and legal actions related to remdesivir use in COVID-19 management within India. This reflects ongoing monitoring and management of remdesivir use in the region in the COVID-19 pandemic context.

Evidence: WHO Guidelines, NICE Guidelines

## Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

## References

- guideline: WHO Guidelines

<https://www.who.int/publications/guidelines>

- guideline: NICE Guidelines

<https://www.nice.org.uk/guidance>

- publication: PMID:39816292

<https://pubmed.ncbi.nlm.nih.gov/39816292/>

- publication: PMID:39811032

<https://pubmed.ncbi.nlm.nih.gov/39811032/>

- publication: PMID:39739156

<https://pubmed.ncbi.nlm.nih.gov/39739156/>

- publication: PMID:39743047

<https://pubmed.ncbi.nlm.nih.gov/39743047/>

- trial: NCT04610541

<https://clinicaltrials.gov/study/NCT04610541>

- trial: NCT04647695

<https://clinicaltrials.gov/study/NCT04647695>

- trial: NCT04345419

<https://clinicaltrials.gov/study/NCT04345419>

- trial: NCT04582266

<https://clinicaltrials.gov/study/NCT04582266>

- trial: NCT04560231

<https://clinicaltrials.gov/study/NCT04560231>

## Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**